| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.
|
Neuron
|
2003
|
6.05
|
|
2
|
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay.
|
J Clin Endocrinol Metab
|
2011
|
1.79
|
|
3
|
Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency.
|
J Clin Endocrinol Metab
|
2011
|
1.62
|
|
4
|
High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports.
|
Clin Chem
|
2009
|
1.60
|
|
5
|
Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody.
|
Structure
|
2012
|
1.57
|
|
6
|
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
|
J Clin Endocrinol Metab
|
2012
|
1.24
|
|
7
|
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.
|
Eur J Endocrinol
|
2011
|
1.13
|
|
8
|
Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
|
J Clin Endocrinol Metab
|
2008
|
1.06
|
|
9
|
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
|
Eur J Endocrinol
|
2006
|
1.05
|
|
10
|
Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.
|
Pituitary
|
2009
|
1.04
|
|
11
|
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
|
J Clin Endocrinol Metab
|
2012
|
1.00
|
|
12
|
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
|
Clin Endocrinol (Oxf)
|
2009
|
0.98
|
|
13
|
Cushing's syndrome due to ACTH-secreting pheochromocytoma.
|
Can J Urol
|
2008
|
0.95
|
|
14
|
Detection of 3,5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay.
|
Thyroid
|
2014
|
0.95
|
|
15
|
Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature.
|
J Clin Psychopharmacol
|
2008
|
0.93
|
|
16
|
Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status--3-year results from the HypoCCS Database.
|
J Clin Endocrinol Metab
|
2002
|
0.93
|
|
17
|
Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature.
|
Eur J Endocrinol
|
2007
|
0.91
|
|
18
|
Growth hormone assays: current methodologies and their limitations.
|
Pituitary
|
2007
|
0.91
|
|
19
|
Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation.
|
J Immunol Methods
|
2006
|
0.90
|
|
20
|
Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module.
|
J Clin Endocrinol Metab
|
2003
|
0.89
|
|
21
|
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
|
J Clin Endocrinol Metab
|
2003
|
0.89
|
|
22
|
Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing.
|
J Clin Endocrinol Metab
|
2004
|
0.88
|
|
23
|
Ghrelin drives GH secretion during fasting in man.
|
Eur J Endocrinol
|
2002
|
0.88
|
|
24
|
Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
|
J Clin Endocrinol Metab
|
2006
|
0.88
|
|
25
|
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database.
|
J Clin Endocrinol Metab
|
2008
|
0.87
|
|
26
|
A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist.
|
Nat Med
|
2007
|
0.85
|
|
27
|
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
|
J Clin Endocrinol Metab
|
2009
|
0.85
|
|
28
|
Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.
|
J Clin Endocrinol Metab
|
2010
|
0.83
|
|
29
|
Technology insight: detecting growth hormone abuse in athletes.
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.83
|
|
30
|
Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects.
|
Psychoneuroendocrinology
|
2004
|
0.82
|
|
31
|
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
|
Eur J Endocrinol
|
2007
|
0.82
|
|
32
|
12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency.
|
Pituitary
|
2013
|
0.82
|
|
33
|
Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions.
|
Clin Sci (Lond)
|
2010
|
0.81
|
|
34
|
Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS).
|
Clin Endocrinol (Oxf)
|
2009
|
0.81
|
|
35
|
Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis.
|
Clin Endocrinol (Oxf)
|
2009
|
0.81
|
|
36
|
Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression.
|
Psychoneuroendocrinology
|
2002
|
0.81
|
|
37
|
Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells.
|
Kidney Int
|
2003
|
0.80
|
|
38
|
Quantification of the soluble leptin receptor in human blood by ligand-mediated immunofunctional assay.
|
J Clin Endocrinol Metab
|
2002
|
0.80
|
|
39
|
Role of placental growth hormone in the alteration of maternal arterial resistance in pregnancy.
|
J Reprod Med
|
2007
|
0.79
|
|
40
|
Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform.
|
J Clin Endocrinol Metab
|
2003
|
0.79
|
|
41
|
Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
|
Clin Chem
|
2012
|
0.78
|
|
42
|
Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
|
Eur J Endocrinol
|
2007
|
0.78
|
|
43
|
Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study.
|
J Clin Endocrinol Metab
|
2014
|
0.78
|
|
44
|
The diagnosis of partial growth hormone deficiency in adults with a putative insult to the hypothalamo-pituitary axis.
|
J Clin Endocrinol Metab
|
2007
|
0.78
|
|
45
|
A new nonisotopic, highly sensitive assay for the measurement of human placental growth hormone: development and clinical implications.
|
J Clin Endocrinol Metab
|
2003
|
0.77
|
|
46
|
Growth hormone.
|
Handb Exp Pharmacol
|
2010
|
0.77
|
|
47
|
IGF-1, IGFBP-3 and ALS in adult patients with chronic kidney disease.
|
Growth Horm IGF Res
|
2009
|
0.77
|
|
48
|
Anxiety modulation by the heart? Aerobic exercise and atrial natriuretic peptide.
|
Psychoneuroendocrinology
|
2006
|
0.77
|
|
49
|
Growth hormone should be used only for approved indications.
|
J Clin Endocrinol Metab
|
2013
|
0.76
|
|
50
|
What endocrinologists should know about growth hormone measurements.
|
Endocrinol Metab Clin North Am
|
2007
|
0.75
|
|
51
|
Effect of different growth hormone (GH) mutants on the regulation of GH-receptor gene transcription in a human hepatoma cell line.
|
Eur J Endocrinol
|
2002
|
0.75
|
|
52
|
Specific monoclonal antibodies and ultrasensitive immunoassays for 20K and 22K human growth hormone.
|
Growth Horm IGF Res
|
2010
|
0.75
|
|
53
|
Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
|
Growth Horm IGF Res
|
2009
|
0.75
|
|
54
|
Decreasing resistance in the maternal uterine and peripheral arterial system is apparently unrelated to plasma and urinary levels of nitrite/nitrate and cyclic-guanosinmonophosohate during the course of normal pregnancies.
|
J Perinat Med
|
2003
|
0.75
|
|
55
|
Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly.
|
Eur J Endocrinol
|
2007
|
0.75
|
|
56
|
Pegvisomant-primed GH stimulation test.
|
Clin Endocrinol (Oxf)
|
2007
|
0.75
|
|
57
|
Can cardiac surgery cause hypopituitarism?
|
Pituitary
|
2012
|
0.75
|
|
58
|
Serum levels of 20K-hGH and 22K-hGH isoforms in acromegalic patients.
|
Front Horm Res
|
2010
|
0.75
|